Antipsychotic Drugs Market Developmental Activities to Boost | AstraZeneca, Pfizer, Eli Lily and Co.

Schizophrenia is the prime cause of psychosis across the globe and patients suffering with the disorder are more likely to succumb to physical and mental illness. According to the World Health Organization (WHO), over 21 million people worldwide were affected with schizophrenia in 2016. The WHO also states that one in two people suffering from schizophrenia do not receive appropriate care for the condition. This creates an opportunity for the market players in the global anti-psychotic drugs market to develop cost-effective medications for the treatment of this disease.

Furthermore, according to the National Alliance of Medical Illness in 2017, around 1.1% adults in the U.S. live with schizophrenia, while 2.6% of the population in the country suffer from bipolar disorder. On an average, 1 in 5 adults, which adds to around 43.8 million people or 18.5% of the total population in the U.S., experience some or the other kind of mental illness in a particular year. High prevalence and increasing incidence of neurological of disorders is supporting growth of the anti-psychotic drugs market.

Get a sample pages of this report@: https://www.coherentmarketinsights.com/insight/request-sample/1196 

On the basis of geography, the global anti-psychotic drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the largest market share in the global anti-psychotic drugs market, attributable to rising prevalence of psychosis among the youth as well increase in the prevalence of schizophrenia among the geriatric population. According to the social stats of National Academy of Mental Illness in 2017, around 70% of youth in the juvenile justice systems in the U.S suffered from at least from one mental health condition, while 20% live with a serious mental illness.

Asia Pacific is expected to exhibit a significant growth in the global anti-psychotic drugs market, owing to government initiatives to improve treatment offered to increasing number of people suffering from mental illness. The World Health Organization (WHO), 2016, Pilot Programs in India, Iran, and Pakistan have exhibited a feasibility in providing care to people suffering from mental disorders such as provision of essential medicines and public education to decrease the stigma and discrimination about mental illness.

Increase in drug abuse and increasing incidence of drug addiction inadvertently fueling growth of global anti-psychotic drugs market

The major driver of the global anti-psychotic drugs market is the increase in prevalence of Schizophrenia and psychotic disorders. Several other factors such as increasing incidence of drug abuse, over prescription of psychotic drugs as well as addiction to the antipsychotic drugs further augment market growth. According to the National Survey on Drug Use and Health (NSDUH), around 13.2% of the population in the U.S. (accounting for nearly 4 million people) used an illicit drug or abused a psychotherapeutic medication in 2012. However, patent expiry of major brands over the last few years has a negative effect on market growth. Moreover, the side effects of anti-psychotics leading to tardive dyskinesia, insomnia, and several other disorders are restraining growth of the global anti-psychotic drugs market.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! @ https://www.coherentmarketinsights.com/insight/request-discount/1196  

Antipsychotic Drug Market Taxonomy:

On the basis of drug type, the global anti-psychotic drugs market is segmented into:

First-generation Drugs (Standard / Typical Antipsychotic Agents)
Thorazine (Chlorpromazine HCl)
Serentil (Mesoridazine Besylate)
Mellaril (Thioridazine HCl)
Haldol (Haloperidol)
Loxitane (Loxapine Succinate)
Trilafon (Perphenazine)
Navane (Thiothixene)
Sordinol (Clopenthixol)
Others
Second-generation Drugs (Atypical Antipsychotic Agents)
Zyprexa (Olanzapine)
Geodon (Ziprasidone)
Seroquel (Quetiapine)
Risperdal (Risperidone)
Clozaril (Clozapine)
Invega (Paliperidone)
Asendin (Amoxapine)
Latuda (Lurasidone)
Others
Third-generation Drugs
Abilify (Aripiprazole)
Others
On the basis of application, the global anti-psychotic drugs market is segmented into:

Schizophrenia
Bipolar Disorder
Dementia
Unipolar Depression
Others
On the basis of distribution channel, the global anti-psychotic drugs market is segmented into:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Key players focusing on development of novel and innovative therapeutic medication to strengthen their presence in the global antipsychotic drugs market

The key players dominating the global antipsychotic drugs market are AstraZeneca, Pfizer, Inc., Eli Lily and Co., Bristol- Myers Squibb, Johnson & Johnson, GlaxoSmithKline, and Allergen. These players are involved in developing innovative drugs for treatment of psychotic diseases with reduced side effects of the drugs to increase the consumption of the product in market. Otsuka Pharmaceuticals in November 2017 received an FDA approval for the first ever antipsychotic drug treatment Abilify MyCite, which is imbued with a digital ingestion tracking system that intends to treat Schizophrenia and acute attacks of bipolar disorder.

Contact us for any query or to get a personalized report@: https://www.coherentmarketinsights.com/insight/request-customization/1196

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.